Prescient Therapeutics Receives European Approval for PTX-100 Phase 2a Trial in Rare T-Cell Lymphoma
Key Insights
Prescient Therapeutics (search) has secured European regulatory approval to begin a Phase 2a clinical trial of PTX-100 for patients with relapsed or refractory Cutaneous T-cell Lymphoma (search) (CTCL).
PTX-100 is a first-in-class inhibitor of geranylgeranyl transferase-1 (search) (GGT-1 (search)) that has received FDA Orphan Drug and Fast Track designations for T-cell lymphomas (search).
The global Phase 2 program aims to enroll up to 40 patients, with the Phase 2a component targeting 20 patients across two dosing arms in Australia, the US, and Europe.
Prescient Therapeutics (search) has achieved a significant regulatory milestone with European authorization to initiate a Phase 2a clinical trial of PTX-100 in patients with relapsed or refractory Cutaneous T-cell Lymphoma (search) (CTCL). The approval, granted through the European Clinical Trials Information System (CTIS), enables trial site activation and patient recruitment in Italy, marking a crucial expansion of the company's global development program.
Novel Mechanism of Action Targets Cancer Cell Growth
PTX-100 represents a first-in-class inhibitor of geranylgeranyl transferase-1 (search) (GGT-1 (search)), a key enzyme involved in cancer cell growth pathways. The therapy works by blocking the activation of Rho (search), Rac (search), and Ral (search) signaling pathways, which induces cancer cell death and disrupts oncogenic Ras-driven processes. According to Prescient, PTX-100 is believed to be the only GGT-1 inhibitor currently in clinical development worldwide.
The drug has demonstrated encouraging early performance, showing safety and preliminary efficacy in previous Phase 1 studies and recently completing a Phase 1b expansion cohort in T-cell lymphomas (search). Building on positive data from the Phase 1b trial in chronic lymphocytic leukemia (search) (CLL) patients, particularly in sub-analyses that demonstrated favorable responses, the Phase 2a study aims to replicate and build on those outcomes.
Regulatory Recognition and Trial Design
The U.S. FDA has granted PTX-100 both Orphan Drug Designation for all T-cell lymphomas (search) and Fast Track Designation for adults with relapsed or refractory mycosis fungoides (search), highlighting the significant unmet medical need in this patient population. The global Phase 2 program aims to enroll up to 40 patients in its Phase 2a component.
CEO James McDonnell emphasized the significance of this authorization, stating, "This authorisation marks a significant milestone for Prescient and for patients living with CTCL. It reflects months of dedicated work by our clinical team and brings us closer to delivering a new treatment option for a disease with high unmet need."
Multi-Regional Development Strategy
The Phase 2a trial will involve up to 20 patients across two dosing arms, with recruitment already underway in Australia and the United States. The first European clinical site will be established in Bologna, Italy, with additional French sites planned to follow once administrative procedures are completed early next year.
McDonnell explained the trial timeline, noting that "the dose optimisation committee will review the data. We're expecting that sometime mid to late next year. Then we'll be able to make decisions on the next part forward." A dose optimization committee is expected to review initial patient data in mid to late 2026, which will help determine the trial's next steps.
Broader Pipeline Development
Alongside its targeted therapies, Prescient continues to advance its next-generation cell therapy platforms, including CellPryme-M, CellPryme-A, and OmniCAR. These complementary technologies are designed to enhance the potency, precision, and durability of engineered T-cell therapies and remain in preclinical and early clinical development.
The company is pursuing a multi-regional approach to clinical development, leveraging regulatory progress in Europe alongside existing operations in the US and Australia. The Phase 2a program remains a key clinical focus as PTX-100 progresses toward broader validation across multiple jurisdictions, with the aim of generating sufficient safety and efficacy data to support future development decisions.